Publication list 16-01-06

Publications
Original Articles
OA-1
Wenzel RR, Spieker LE, Su Q, Lüscher TF, Noll G (1998). Inhibition of muscle sympathetic nerve activityby moxonidine in patients with essential hypertension. Hypertension 32:1022-7. Impact Factor: 5.6 Spieker LE, Noll G, Lüscher TF (2000). Efficacy and tolerability of fluvastatin and bezafibrate in patientswith hyperlipidemia and persistantly high triglyceride levels. J Cardiovasc Pharmacol 35:361-5. ImpactFactor: 1.9 Spieker LE, Noll G, Mitrovic V, Pacher R, Schulze M, Muntwyler J, Schalcher C, Kiowski W, Lüscher TF(2000). Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patientswith congestive heart failure. J Am Coll Cardiol 35:1745-52. Impact Factor: 7.6 Spieker LE, Corti R, Binggeli C, Lüscher TF, Noll G (2000). Baroreceptor dysfunction induced by nitricoxide synthase inhibition in man. J Am Coll Cardiol 36:213-8. Impact Factor: 7.6 Binggeli C, Duru F, Corti R, Sudano I, Spieker LE, Turina A, Westermann P, Ostermeier M, Rahn M,Luscher TF, Noll G, Candinas R (2000). Autonomic nervous system-controlled cardiac pacing: acomparison between intracardiac impedance signal and muscle sympathetic nerve activity. Pacing ClinElectrophysiol 23:1632-7. Impact Factor: 1.4 Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Ruschitzka F, Corti R, Lüscher TF,Noll G (2002). High-density lipoprotein restores endothelial function in hypercholesterolemic men.
Circulation 105:1399-402. Impact Factor: 11.2 Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, Hayoz D, Deanfield JE, Lüscher TF,Noll G (2002). Mental stress induces prolonged endothelial dysfunction via endothelin A receptors.
Circulation 105:2817-20. Impact Factor: 11.2 Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M,Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F (2002). Anti-tumor necrosis factor-α treatmentimproves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184-7. ImpactFactor: 11.2 Corti R, Binggeli C, Sudano I, Spieker LE, Hänseler E, Ruschitzka F, Chaplin WF, Lüscher TF, Noll G(2002). Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeinecontent. Role of habitual versus nonhabitual drinking. Circulation 106:2935-40. Impact Factor: 11.2 OA-10 Chenevard R, Hürlimann D, Béchir M, Enseleit F, Spieker LE, Hermann M, Riesen W, Gay S, Gay R, Neidhart M, Lüscher TF, Noll G, Ruschitzka F (2003). COX-2 inhibition improves endothelial function inpatients with coronary artery disease. Circulation 107:405-9. Impact Factor: 11.2 OA-11 Binggeli C, Spieker LE, Corti R, Sudano I, Stojanovic V, Hayoz D, Lüscher TF, Noll G (2003). Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoringtest of endothelial dysfunction for clinical practice? J Am Coll Cardiol 41:71-7. Impact Factor: 7.6 OA-12 Béchir M, Binggeli C, Corti R, Chenevard R, Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003).
Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vasovagal syncope.
Circulation 107:1620-5. Impact Factor: 11.2 OA-13 Spieker LE, Lüscher TF, Noll G (2003). ET(A) receptors mediate vasoconstriction of large conduit arteries during reduced flow in man. J Cardiovasc Pharmacol 42;315-8. Impact Factor: 1.9 OA-14 Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R (2004). Shear stress-dependent platelet function after LDL cholesterol apheresis. Thrombosis Research 113:395-8. Impact Factor: 1.7 OA-15 Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M, Riesen W, Neidhart M, Michel BA, Hellermann JP, Gay RE, Luscher TF, Gay S, Noll G, Ruschitzka F.
(2005). Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am CollCardiol 45:461-4. Impact Factor: 7.6 OA-16 Stojanovic V, Küng F, Spieker LE, Binggeli C, Sudano I, Hayoz D, Lüscher TF, Noll G (2005). Estrogens increase postischemic hyperemia in the skin microcirculation of healthy women. J Cardiovasc Pharmacol45:414-7. Impact Factor: 1.9 OA-17 Hermann F, Spieker LE, Ruschitzka F, Sudano I, Hermann M, Binggeli C, Luscher TF, Riesen W, Noll G, Corti R (2006). Swiss dark chocolate improves endothelial and platelet function in smokers. Heart92:119-20. Impact Factor: 3.2 OA-18 Sudano I, Spieker LE, Binggeli C, Ruschitzka F, Lüscher TF, Noll G, Corti R (2005). Coffee blunts mental Publication List of Lukas Spieker – August 29, 2006 – Page 2 stress–induced blood pressure increase in habitual but not in nonhabitual coffee drinkers. Hypertension46:621-6. Impact Factor: 5.6 OA-19 Flammer A, Spieker LE, Amacker N, Badimon JJ, Sasse B, Ruschitzka F, Noll G, Corti R (2006, In print).
C-reactive protein influences shear stress-dependent platelet adhesion in patients with familiarhypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis andHaemostasis. Impact Factor: 4.5 OA-20 Maas R, Quitzau K, Schwedhelm E, Spieker LE, Rafflenbeul W, Steenpass A, Luscher TF, Boger RH (2006). Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients withcoronary artery disease and mild hypercholesterolemia. Atherosclerosis [Epub ahead of print] ImpactFactor: 3.8 Cumulative Impact Factor (Original Articles): 128.8 Review Articles and Editorials
RA-1
Spieker LE, Binggeli C, Lüscher TF, Noll G (1997). Mitleid und Herzschmerz: Neues vom Sympathikus.
Schweiz Med Wschrft 127:1986-1992. Impact Factor: 1.2 Spieker LE, Lüscher TF, Noll G (2000). Das sympathische Nervensystem bei der arteriellen Hypertonie:Verbindung von Seele und Kreislauf? Medizinspiegel 3:7-12. Impact Factor: – Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF (2000). Working under pressure – Theendothelium in arterial hypertension. J Hum Hypertens 14:617-630. Impact Factor: 1.4 Spieker LE, Lüscher TF, Noll G (2000). Homocystein als kardiovaskulärer Risikofaktor. KardiovaskuläreMedizin 3:184-95. Impact Factor: – Corti R, Binggeli C, Sudano I, Spieker LE, Wenzel RR, Lüscher TF, Noll G (2000). The beauty and thebeast: Aspects of the autonomic nervous system. News In Physiological Sciences 15:125-129. ImpactFactor: 3.7 Spieker LE, Noll G, Lüscher TF (2001). Therapeutic potential of endothelin receptor antagonists incardiovascular disorders. Am J Cardiovasc Drugs 1;293-303. Impact Factor: – Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heartfailure – Blocking the beast while leaving the beauty untouched? Heart Fail Rev 6:301-15. ImpactFactor: – Spieker LE, Lüscher TF, Noll G (2001). Beyond traditional risk factors: Homocystein and atherosclerosis.
Heartdrug 1:160-8. Impact Factor: – Spieker LE, Lüscher TF, Noll G (2001). Current strategies and perspectives for correcting endothelialdysfunction in atherosclerosis. J Cardiovasc Pharmacol. 38(Suppl 2):S35-41. Impact Factor: 1.9 RA-10 Lüscher TF, Spieker LE, Noll G, Cosentino F (2001). Vascular effects of newer cardiovascular drugs: Focus on nebivolol and ACE-inhibitors. J Cardiovasc Pharmacol. 38(Suppl 3):S3-11. Impact Factor: 1.9 RA-11 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (2001). Endothelin receptor antagonists in congestive heart failure – A new therapeutic principle for the future? J Am Coll Cardiol 37:1493-505. Impact Factor: 7.6 RA-12 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2001). Die Diagnose der Herzinsuffizienz. Therapiewoche RA-13 Spieker LE, Lüscher TF (2001). Kardiovaskuläre Prävention – kulinarisch oder klinisch? Kardiovaskuläre RA-14 Spieker LE, Eberli FR, Buser P, Mach F, Beer J, Urban P, Noll G, Rickenbacher P, Pfisterer M, Meier B, Lüscher TF (2002). Plättchenhemmung durch Thienopyridine beim akuten Koronarsyndrom – praktischeEmpfehlungen aufgrund der CURE Studie. Kardiovaskuläre Medizin 5:61-71. Impact Factor: – RA-15 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2002). The management of hyperuricemia and gout in patients with congestive heart failure. European J Heart Failure 4:403-10. Impact Factor: 2.9 RA-16 Spieker LE, Lüscher TF (2003). Will endothelin receptor antagonists have a role in heart failure? Med RA-17 Spieker LE, Lüscher TF (2003). Endothelin receptor antagonists in heart failure – A refutation of a bold conjecture? European Journal of Heart Failure 5;415-7. Impact Factor: 2.9 RA-18 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2003). Medikamentöse Therapie der Herzinsuffizienz.
RA-19 Spieker LE, Corti R, Hellermann JP, Eberli FR, Noll G, Lüscher TF. (2003) Niedermolekulare Heparine Publication List of Lukas Spieker – August 29, 2006 – Page 3 beim akuten Koronarsyndrom – Ist Enoxaparin überlegen? Kardiovaskuläre Medizin 6:238-47. ImpactFactor: – RA-20 Spieker LE, Noll G (2003). Pathophysiologische Herz-Kreislaufveränderungen bei Stress und Depression.
Therapeutische Umschau 60:667-72. Impact Factor: – RA-21 Spieker LE, Ruschitzka F, Noll G (2003). HDL-Cholesterin bei Atherosklerose – Zuwenig des Guten.
Schweizerisches Medizin Forum 39:920-6. Impact Factor: – RA-22 Spieker LE, Ruschitzka F, Lüscher TF, Noll G (2004). HDL and inflammation in atherosclerosis. Current Drug Target – Immune, Endocrine and Metabolic Disorders 4:51-57. Impact Factor: – RA-23 Corti R, Spieker LE, Mach F, Erne P, Moccetti T, Beer J, Urban P, Buser P, Rickenbacher P, Pfisterer M, Eberli FR, Bertel O, Meier B, Lüscher TF (2004). Plättchenhemmung durch Thienopyridine beim akutenKoronarsyndrom und nach perkutaner koronarer Intervention – praktische Empfehlungen.
Kardiovaskuläre Medizin 7;159-73. Impact Factor: – RA-24 Spieker LE, Lüscher TF (2004). Die Rolle der Angiotensin II-Antagonisten in der antihypertensiven Pharmakotherapie. Ars Medici 12;595-8. Impact Factor: – RA-25 Spieker LE (2004). Das Herz beim metabolischen Syndrom. Kardiovaskuläre Medizin 7:317-24. Impact RA-26 Spieker LE (2004). Vorhersage kardiovaskulärer Ereignisse: Endothelfunktion als Surrogatmarker.
RA-27 Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ (2005).
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. Astatement by the Working Group on Endothelins and Endothelial Factors of the European Society ofHypertension. J Hypertens 23:233-246. Impact Factor: 1.6 RA-28 Spieker LE, Stacchi R, Corti R, Noll G (2005). Der Cannabinoid-Rezeptor-Antagonist Rimonabant.
Kardiovaskuläre Medizin 8;18-22. Impact Factor: – RA-29 Sudano I, Binggeli C, Spieker LE, Lüscher TF, Ruschitzka F, Noll G, Corti R (2005). Cardiovascular effects of coffee: is it a risk factor? Prog Cardiovasc Nurs 20:65-9.Impact Factor: – RA-29 Sudano I, Spieker LE, Corti R, Weber R, Lüscher TF (2006). Cardiovascular disease in HIV infection. Am RA-30 Spieker LE, Noll G, Ruschitzka F, Lüscher TF (Submitted). The challenge of diagnosing heart failure.
RA-31 Hollenberg NK, Schmitz H, Spieker LE, Lüscher TF, MacDonald I, Poulter N (In press). Dietary flavonoids and cardiovascular risk. British Journal of Cardiology.
RA-32 Hermann F, Ruschitzka F, Spieker L, Sudano I, Noll G, Corti R (2005). The sweet secret of dark chocolate. Ther Umsch 62:635-7. Impact Factor: – RA-33 Corti R, Sudano I, Spieker L, Binggeli C, Hermann F, Toenz D, Noll G (2005). Coffee – poison or medicine? Ther Umsch 62:629-33. Impact Factor: – RA-34 Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, Luscher TF (2006). Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol47 Suppl 2:S136-50. Impact Factor: 1.9 Cumulative Impact Factor (Review Articles): 35.4 Case Reports
CR-1
Spieker LE, Sütsch G (2003). Eine 22-jährige Frau mit akutem Myokardinfarkt. Kardiovaskuläre Medizin6:162-4. Impact Factor: – Karadag B, Spieker LE, Schwitter J, Ruschitzka F, Noll G, Lüscher TF, Corti R (2004). Lyme carditis:restitutio ad integrum documented by cardiac MRI. Cardiology in Review 12:185-7. Impact Factor: – Spieker LE, Hufschmid U, Oechslin E, Jenni R (2004). Double aortic and pulmonary valves: an artifactgenerated by ultrasound refraction. J Am Soc Echocardiogr 17:786-7. Impact Factor: 1.4 Spieker LE, Jenni R (2004). An apparently immobile mitral valve prosthesis leaflet. J Am SocEchocardiogr 17;905. Impact Factor: 1.4 Spieker LE, Maier W, Jenni R (2004). Eine Frau mit intramyokardialer Verkalkung. KardiovaskuläreMedizin 7:218-20. Impact Factor: – Karadag B, Spieker LE, Wildermut S, Maier W, Böhm T, Lüscher TF, Corti R (2005). Sudden death in a Publication List of Lukas Spieker – August 29, 2006 – Page 4 soccer player: A unique case of anomalous coronary origin detected by 16-slice computed tomographyimaging. Heart and Vessels 20:116-9. Impact Factor: 0.4 Spieker LE, Karadag B, Binggeli C, Corti R (2005). Rapid progression of atherosclerotic coronary arterydisease in patients with HIV infection. Heart and Vessels 20;171-4. Impact Factor: 0.4 Spieker LE, Corti R, Noll G (2005). Eine Frau mit Bradykardie und Schwäche. Schweiz Med Forum5;60-2. Impact Factor: – Spieker LE, Burger P, Ritschard T, Noti C, Corti R (In print). Ein gebrochenes Herz nach einem Streit mitder Schwiegermutter: die Stress-induzierte Kardiomyopathie. Kardiovaskuläre Medizin. Impact Factor: – Cumulative Impact Factor (Case Reports): 3.6 Book Chapters
B-1
Spieker LE, Noll G, Ruschitzka F, Maier W, Lüscher TF. Endothelial function in hypertension. In: SchwartzCJ, Born GVR (Eds). Occlusive arterial disease. The interfaces among dyslipidemia, hypertension anddiabetes. Schattauer (2001).
Spieker LE, Lüscher TF. Hypertension and blood vessels: from diagnosing vascular events to theassessment of endothelial dysfunction. In: Birkenhäger WH, Robertson JIS, Zanchetti A (Eds). Handbookof Hypertension, Vol. 22: Hypertension in the twentieth century. Elsevier (2004).
Spieker LE, Lüscher TF. Target Organ Damage: Endothelium and Vessels. In: Distance-learning course:Clinical Hypertension (2004). www.emn.net Spieker LE, Lüscher TF. Endothelium in hypertension: Nitric oxide. In: Oparil S, Weber MA (Eds).
Hypertension: A companion to Brenner and Rector’s The Kidney, 2nd Ed. Elsevier (2005).
Spieker LE, Lüscher TF. Endothelium, vascular smooth muscle, perturbations of cell membranes andsignal transduction in hypertension. In: Battegay E, Lip GYH, Bakris GL (Eds.). Hypertension: Principlesand practice. Dekker (In press).
Lüscher TF, Noll G, Spieker LE, Corti R, Pepine CJ. Coronary spasm and atherothrombosis. In: Fuster V,Nabel EG, Topol EJ (Eds). Atherothrombosis and coronary artery disease, 2nd Ed. Lippincott Williams &Wilkins (2005).
Spieker LE, Lüscher TF. Protection of endothelial function (2005). Handbook of experimentalpharmacology Handb Exp Pharmacol 170:619-44.
Invited Lectures and Presentations (Selection)
P-1
European Society of Cardiology (ESC), Stockholm 1997. Variability of muscle sympathetic nerve activity,arterial blood pressure, and heart rate. Schweizerische Gesellschaft für Kardiologie (SGK), Interlaken 1998. Wirkung von NO-Synthese-Hemmung auf Hämodynamik und Sympathikus.
Lipid-Symposium, Zürich 1999. Hyperhomocysteinämie: klinische Bedeutung und Therapie.
6th Endothelin-Meeting, Montreal 1999. Acute hemodynamic and neurohumoral effects of selective ETAreceptor blockade in patients with congestive heart failure.
European Society of Cardiology (ESC), Barcelona 1999. Effects of NO synthase inhibition on musclesympathetic nerve activity and hemodynamics in man.
American Heart Association (AHA), New Orleans 2000. High-density lipoprotein restores endothelialfunction in hypercholesterolemic men.
American College of Cardiology (ACC), Anaheim 2000. Baroreceptor dysfunction induced by nitric oxidesynthase inhibition in man.
Lipid-Symposium, Zürich 2000. Stress und Endothelfunktion.
European Society for Clinical Investigation (ESCI), Barcelona 2001. HDL restores endothelial function inhypercholesterolemic men.
Schweizerische Gesellschaft für Kardiologie (SGK), Zürich 2001. Endothelin-1 mediates vasoconstrictionof large conduit arteries during reduced flow via endothelin A receptors in man.
Lipid-Symposium, Zürich 2002. Neue Cholesterinsenker.
Evidence-based Cardiology, Feusisberg 2002. The patient with multiple risk factors.
The Menarini Series on Atherosclerosis, Naples 2002. Pharmacological modulation of the endothelium Publication List of Lukas Spieker – August 29, 2006 – Page 5 1st International Meeting on ADMA as a Cardiovascular Risk Factor, Hamburg 2002. Pharmacotherapyof coronary endothelial dysfunction. Klinisch-wissenschaftliche Konferenz, USZ, Zürich 2002. HDL – Protektive Wirkung über denLipidstoffwechsel hinaus.
American Heart Association (AHA), Chicago 2002. Mental stress induces prolonged endothelialdysfunction via endothelin A receptors.
Zürich 2002. Angiotensin II-Rezeptor Antagonisten in der Prävention kardiovaskulärer Endorgan-Schäden.
Herzkreislauftag, Zürich 2002. Klinische Entscheidungen bei multimorbiden Herzpatienten.
Zürich 2003. Duale Cholesterintherapie mit Ezetimibe und Statinen.
American College of Cardiology (ACC), Chicago 2003. Marked coronary endothelial dysfunction inpatients with low HDL and elevated C-reactive protein.
Schweizerische Gesellschaft für Kardiologie, Lausanne 2003. AIDS – eine kardiovaskuläre Krankheit? Hellenic Cardiology Society, Santorini 2003. Inflammation and atheroslerosis – Does the endotheliumprovide a link? Zürich 2003. Arterielle Hypertonie – Optimaler medikamentöser Endorganschutz.
Schweizerische Gesellschaft für Innere Medizin 2003. Pathophysiologie der Herz-Kreislaufveränderungenbei Depression und Stress.
Aging Forum, Bad Aibling 2003. Mental stress and atherosclerosis.
Tag der offenen Tür, Kardiologie USZ 2003. Wie bleibt mein Herz gesund? 6th Winter Meeting, Working Group on Heart Failure, Swiss Cardiology Society, Mürren 2004. Heartfailure therapy in post-MI and DCM patients: Two pairs of shoes? Zürich 2004. Cholesterintherapie – wie weiter? Controversies in Cardiology, Bern 2004. Erectile Dysfunction – an unsolved problem.
Schweizerische Gesellschaft für Kardiologie, Basel 2004. Metabolic syndrome – the cardiologists view.
Evidence-based Cardiology, Feusisberg 2004. The patient with multiple risk factors.
Evidence-based Cardiology, Feusisberg 2004. Treatment of acute coronary syndrome.
Symposium für Akutgeriatrie, Stadtspital Waid, Zürich 2005. Phosphodiesterasehemmer – kein Problemim Alter.
Herzkreislauf-Erkrankungen. Kurs für Pflegende. Universitätsstpital Zürich, 2004 und 2005.
Fallvorstellung, Herzinsuffizienz-Update, Grenchen 2005.
Herznotfall: aus der Sicht des Praktikers. HerzZentrum Bern, Bern 2006.

Source: http://www.cordix.ch/publikationen.pdf